JNJ-87189401

N/A

Report date: 2026/05/15 15:28:49

Base Information

Drug NameJNJ-87189401

Drug Alias NamePSMAxCD28PSMA-CD28 Bispecific AntibodyJNJ-87189401

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD28

TargetsProstate-Specific Membrane AntigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceMainland China +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesJanssen Research & Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A